Dashboard
Weak Long Term Fundamental Strength with a 21.71% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 8.42 times
- The company has been able to generate a Return on Capital Employed (avg) of 8.07% signifying low profitability per unit of total capital (equity and debt)
Stock is technically in a Mildly Bearish range
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Other Agricultural Products
INR 68 Cr (Micro Cap)
34.00
32
0.00%
1.70
2.28%
0.98
Total Returns (Price + Dividend) 
Indrayani Biotec for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Indrayani Biotech Ltd Upgraded to Hold on Improving Financials and Valuation
Indrayani Biotech Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 16 Nov 2026. This change reflects a nuanced improvement across key parameters including quality, valuation, financial trends, and technical indicators, signalling a cautious but positive outlook for investors.
Read More
Indrayani Biotech Ltd is Rated Sell
Indrayani Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Oct 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Indrayani Biotech Ltd is Rated Sell by MarketsMOJO
Indrayani Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
10-Nov-2026 | Source : BSEIntimation of News Paper publication for the matters relating to Rights Issue.
Reg. 34 (1) Annual Report.
07-Nov-2026 | Source : BSEAnnual Report of the Company for the Financial year ended March 31 2026.
Receipt Of Listing Approval
06-Nov-2026 | Source : BSECompany has received on Listing Approval from BSE for the Proposed Rights issue.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Indrayani Biotech Ltd has announced 5:7 rights issue, ex-date: 28 Apr 26
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
24.839
Held by 0 Schemes
Held by 0 FIIs
G Swaminathan (9.07%)
Jayaseelan Singaravelu (8.12%)
49.64%
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
YoY Growth in quarter ended Jun 2026 is 29.59% vs -7.71% in Jun 2025
YoY Growth in quarter ended Jun 2026 is 237.50% vs -81.18% in Jun 2025
Half Yearly Results Snapshot (Consolidated) - Sep'24
Growth in half year ended Sep 2024 is -24.66% vs 22.25% in Sep 2023
Growth in half year ended Sep 2024 is -59.88% vs -26.70% in Sep 2023
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is -34.62% vs 7.17% in Dec 2023
YoY Growth in nine months ended Dec 2024 is -62.98% vs -34.32% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 5.84% vs -21.66% in Mar 2025
YoY Growth in year ended Mar 2026 is 238.46% vs -124.53% in Mar 2025